While managing cancer risk is a priority, BRCA mutation carriers are often concerned about their risk of heart disease-the leading cause of death for American women-and how their mutation or risk-management choices may impact their cardiovascular health.
Decline seen for older adults but rates are rising for young adults.
The addition of the GM-CSF agent sargramostim to the CTLA-4 inhibitor ipilimumab (Yervoy) prolonged overall survival (OS) and lowered toxicity for patients with unresectable stage III or IV melanoma.
The Bonnie J. Addario Lung Cancer Foundation (ALCF), in collaboration with Open Health Network (OHN), announced the launch of Lung Cancer Foundation, the first of its kind mobile application designed to empower lung cancer patients and their families.
A third of patients die within a week of initiating hospice care.
The FDA has approved the PARP inhibitor olaparib (Lynparza) for the treatment of women with BRCA-positive advanced ovarian cancer. The approval was based on results from a single-arm phase II study of patients with deleterious or suspected deleterious germline BRCA-mutated advanced cancers
There's another type of toxicity that physicians and nurses should watch out for. But this one is harder to spot and can affect the patient even after treatment has stopped.
Women Against Prostate Cancer provide tips to encourage men to be healthier and signs of prostate cancer to be aware of
New research has found that the overall survival of male patients with breast cancer has improved over time, but the improvement is not as good as it has been for female patients with breast cancer
A third of patients in a large study reported distress within the prior month
New research presented at the 2014 San Antonio Breast Cancer Symposium has shown that women with triple-negative breast cancer (TNBC) are more likely to seek out information about their specific subtype and experience more fear, anxiety, and worry than women with other subtypes of breast cancer,
Findings from a long-term analysis of the Women's Intervention Nutrition Study (WINS) show that the deaths of women with hormone receptor–negative breast cancers were reduced by up to 54% when they followed a program to reduce their dietary fat intake, which could provide benefit for patients with triple-negative breast cancer.
Five years of tamoxifen continues to offer protection against breast cancer, reducing the risk of breast cancer by 29% in otherwise healthy women at high risk of the disease who have been followed now for 16 to 22 years.
For individuals living in rural areas, getting a genetic test can impose its own set of barriers, like multiple long trips for counseling, testing, and follow-up. However, findings of a new study published in the Journal of the National Cancer Institute have shown that telephone counseling was just as effective as in-person counseling in many respects.
Survival for patients with head and neck cancer squamous cell carcinoma (HNSCC) was better if they used a proton-pump inhibitor and/or a histamine receptor-2 antagonist to control acid reflux.
Considering participation in a clinical trial is often a very difficult decision for patients, especially those dealing with a rare disease.
Despite research findings that toxicities outweigh benefits when women over the age of 70 are treated with radiation for their early-stage breast cancer, the treatment remains commonplace 10 years later, a new study has found.
The FDA has granted an accelerated approval to the anti-CD19 immunotherapy blinatumomab as a treatment for patients with Philadelphia chromosome-negative relapsed/refractory B-precursor acute lymphoblastic leukemia.
Two studies suggest that treatment during pregnancy does not appear to negatively impact neurologic or cardiac fetal development.
The FDA has approved ruxolitinib (Jakafi) as a treatment for patients with polycythemia vera (PV) who are resistant or intolerant to hydroxyurea, marking the first treatment specifically approved for patients with PV.
A group of researchers looking to better equip patients to be self-managers of their cancer have developed a new tool to help patients communicate their treatment goals more effectively.
Despite the proven benefits of SBRT for patients with inoperable stage I NSCLC, whether such patients are offered it depends on their race, insurance status, and the type of facility where they are being treated.
We are pleased to open the application period for our annual Fellows Symposium.
A genomic test (also called a genomic assay) analyzes the activity of a group of genes linked to the risk of a particular disease.
Alain H. Rook, MD, Professor of Dermatology, University of Pennsylvania, Perelman School of Medicine provides part one of a three part overview of treatments for cutaneous lymphoma.
After 4 years of living with inflammatory breast cancer, Amy Berman, RN, BS, senior program officer at the John A. Hartford Foundation, said she felt fine during her speech at The American Journal of Managed Care's Patient-Centered Oncology Care meeting in Baltimore, Maryland.
The Colon Cancer Alliance is holding a summit, titled "Fighting a Smarter War on Colorectal Cancer" on December 4-6th.
Unusual, but does occur.
With open enrollment now underway to sign up for or change their coverage under the Affordable Care Act, oncology nurses and navigators may be hearing questions from cancer patients, survivors, and their family members about navigating this still relatively new insurance marketplace.
The poly (ADP-ribose) polymerase (PARP) inhibitor veliparib exhibits antitumor activity and is safe and tolerable on a continuous dosing schedule when used for the treatment of patients with BRCA-positive and BRCA–wild type tumors.
